Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome

• Published in: International Urogynecology Journal Vol. 22; no. 4; pp. 395 - 400
• Main Authors: Anger, Jennifer T., Zabihi, Nasim, Clemens, J. Quentin, Payne, Christopher K., Saigal, Christopher S., Rodriguez, Larissa V.
• Format: Journal Article
• Language: English
• Published: London Springer-Verlag 01.04.2011; Springer Nature B.V
• Subjects: Administration, Intravesical; Administration, Oral; Adrenergic Uptake Inhibitors - economics; Adrenergic Uptake Inhibitors - therapeutic use; Adult; Aged; Amines - economics; Amines - therapeutic use; Amitriptyline - economics; Amitriptyline - therapeutic use; Anticoagulants - economics; Anticoagulants - therapeutic use; Cyclohexanecarboxylic Acids - economics; Cyclohexanecarboxylic Acids - therapeutic use; Cystitis, Interstitial - drug therapy; Cystitis, Interstitial - economics; Female; Gabapentin; gamma-Aminobutyric Acid - economics; gamma-Aminobutyric Acid - therapeutic use; Gynecology; Humans; Medicine; Medicine & Public Health; Middle Aged; Muscarinic Antagonists - economics; Muscarinic Antagonists - therapeutic use; Narcotics - economics; Narcotics - therapeutic use; Original; Original Article; Pentosan Sulfuric Polyester - economics; Pentosan Sulfuric Polyester - therapeutic use; Practice Patterns, Physicians; Treatment Outcome; Urology; Young Adult; Treatment; Bladder pain; Claims data; Cost; Ingenix; Interstitial cystitis
• ISSN: 0937-3462; 1433-3023
• DOI: 10.1007/s00192-010-1252-8

Introduction and hypothesis In order to better understand provider treatment patterns for interstitial cystitis (IC)/painful bladder syndrome, we sought to document the therapies utilized and their associated expenditures using a national dataset. Methods A cohort was created by applying the ICD-9 diagnosis of IC (595.1) to INGENIX claims for the year 1999. Subjects were followed for 5 years, and patterns of care and related expenditures were evaluated. Results Of 553,910 adults insured in 1999, 89 subjects had a diagnosis of IC with 5-year follow-up data. All subjects were treated with oral medication(s), 26% received intravesical treatments, and 22% underwent hydrodistension. Total expenditures per subject were $2,808. Conclusions The majority of IC expenditures were attributable to oral medical therapy. Hydrodistension and intravesical instillations were utilized in less than 25% of patients. Hydrodistension was used more frequently among subjects with a new diagnosis; this may reflect its utilization as part of a diagnostic algorithm.